Costs and effects of chlamydial screening: Dynamic versus static modeling

Sexually Transmitted Diseases

Volumn 32, Issue 8, 2005, Pages 474-483

  Welte, Robert ^a,b   Postma, Maarten ^c   Leidl, Reiner ^a   Kretzschmar, Mirjam ^b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CONJUNCTIVITIS; CONSULTATION; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; ECTOPIC PREGNANCY; EPIDIDYMITIS; FEMALE; FERTILIZATION IN VITRO; HUMAN; INFERTILITY; LIGASE CHAIN REACTION; MONTE CARLO METHOD; NETHERLANDS; NORMAL HUMAN; PELVIS PAIN SYNDROME; PRESCRIPTION; PREVALENCE; SCREENING; SENSITIVITY ANALYSIS; URETHRITIS; UTERINE CERVICITIS;

ADOLESCENT; ADULT; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; MALE; MASS SCREENING; MODELS, ECONOMETRIC; NETHERLANDS; STOCHASTIC PROCESSES;

EID: 23044460348     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.olq.0000161181.48687.cf     Document Type: Article

References (35)

1. Peipert JF. Clinical practice. Genital chlamydial infections. N Engl J Med 2003; 349:2424-2430.
2. Kamwendo F, Forslin L, Bodin L, Danielsson D. Decreasing incidences of gonorrhea- and chlamydia-associated acute pelvic inflammatory disease. A 25-year study from an urban area of central Sweden. Sex Transm Dis 1996; 23:384-391.
3. Kamwendo F, Forslin L, Bodin L, Danielsson D. Programmes to reduce pelvic inflammatory disease-The Swedish experience. Lancet 1998; 351(suppl 3):25-28.
4. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance, 2002. Atlanta, US: US Department of Health and Human Services, CDC, September 2003.
5. Scholes D, Stergachis A, Heidrich FE, Andrilla H, Holmes KK, Stamm WE. Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection. N Engl J Med 1996; 334:1362-1366.
6. Welte R, Jager HC, Postma MJ. Cost-effectiveness of screening for genital Chlamydia trachomatis. Expert Rev Pharmacoeconomics Outcomes Res 2001; 1:145-156.
7. Kretzschmar M, van Duynhoven YT, Severijnen AJ. Modeling prevention strategies for gonorrhea and chlamydia using stochastic network simulations. Am J Epidemiol 1996; 144:306-317.
8. Kretzschmar M, Welte R, van den Hoek A, Postma MJ. Comparative model-based analysis of screening programs for Chlamydia trachomatis infections. Am J Epidemiol 2001; 153:90-101.
9. Welte R, Kretzschmar M, Leidl R, van den Hoek A, Jager JC, Postma MJ. Cost-effectiveness of screening programs for Chlamydia trachomatis: A population-based dynamic approach. Sex Transm Dis 2000; 27:518-529.
10. Nyari T, Woodward M, Kovacs L. Should all sexually active young women in Hungary be screened for Chlamydia trachomatis? Eur J Obstet Gynecol Reprod Biol 2003; 106:55-59.
11. Wang LY, Burstein GR, Cohen DA. An economic evaluation of a school-based sexually transmitted disease screening program. Sex Transm Dis 2002; 29:737-745.
12. Mehta SD, Bishai D, Howell MR, Rothman RE, Quinn TC, Zenilman JM. Cost-effectiveness of five strategies for gonorrhea and chlamydia control among female and male emergency department patients. Sex Transm Dis 2002; 29:83-91.
13. Gift T, Walsh C, Haddix A, Irwin KL. A cost-effectiveness evaluation of testing and treatment of Chlamydia trachomatis infection among asymptomatic women infected with Neisseria gonorrhoeae. Sex Transm Dis 2002; 29:542-551.
14. Mrus JM, Biro FM, Huang B, Tsevat J. Evaluating adolescents in juvenile detention facilities for urogenital chlamydial infection: Costs and effectiveness of alternative interventions. Arch Pediatr Adolesc Med 2003; 157:696-702.
15. Blake DR, Gaydos CA, Quinn TC. Cost-effectiveness analysis of screening adolescent males for chlamydia on admission to detention. Sex Transm Dis 2004; 31:85-95.
16. Ginocchio RH, Veenstra DL, Connell FA, Marrazzo JM. The clinical and economic consequences of screening young men for genital chlamydial infection. Sex Transm Dis 2003; 30:99-106.
17. College voor zorgverzekeringen. Richtlijnen voor farmaco-economisch onderzoek. Amstelveen: College voor zorgverzekeringen, 1999.
18. Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-effectiveness in Health and Medicine. Oxford: Oxford University Press, 1996.
19. Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost-effectiveness of vaccination programmes: A dynamic perspective. Stat Med 1999; 18:3263-3282.
20. Van Zessen G, Sandfort T. Seksualiteit in Nederland: Seksuel Gedrag, Risico en Preventie van AIDS. Amsterdam: Swets & Zeitlinger, 1991.
21. Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: The impact of herd-immunity. Med Decis Making 2003; 23:76-82.
22. Townshend JRP, Turner HS. Analysing the effectiveness of chlamydia screening. Journal of the Operational Research Society 2000; 51: 812-824.
23. Beutels P, Edmunds WJ, Antonanzas F, et al. Economic evaluation of vaccination programmes: A consensus statement focusing on viral hepatitis. Pharmacoeconomics 2002; 20:1-7.
24. Kermack WO, McKendrieck AG. Contributions to the mathematical theory of epidemics. Part 1. Proc R Soc Edin A 1927; 115:700-721.
25. Anderson RM, May RM. Infectious Diseases of Humans Dynamics and Controls. Oxford: Oxford University Press, 1991.
26. Eames KTD, Keeling MJ. Monogamous networks and the spread of sexually transmitted diseases. Math Biosci 1994; 189:115-130.
27. Kretzschmar M. Sexual network structure and sexually transmitted disease prevention: A modeling perspective. Sex Transm Dis 2000; 27:627-635.
28. Fine PE. Herd immunity: history, theory, practice. Epidemiol Rev 1993; 15:265-302.
29. Welte R, Feenstra T, Jager H, Leidl R. A decision chart for assessing and improving the transferability of economic evaluation results between countries. Pharmacoeconomics 2004; 22:857-876.
30. Ostergaard L, Anderson B, Moller JK, Diesen F. Screening for klamydia med hijmmetest-en medicinsk teknologivurdering. Copenhagen: Sundhedsstyrelsen, Center for Evaluering og Medicinsk Teknologivurdering, 2002.
31. Roberts T, Robinson S, Barton P, et al. The correct approach to modelling and evaluating chlamydia screening. Sex Transm Infect 2004; 80:324-325.
32. Loomis WP, Starnbach MN. T cell response to Chlamydia trachomatis. Curr Opin Microbiol 2002; 5:87-91.
33. Somani J, Bhullar VB, Workowski KAW, Farshy CE, Black CM. Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis 2000; 181:1421-1427.
34. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. MMWR Recomm Rep 2002; 51:1-78.
35. Organisation for Economic Co-operation and Development. OECD Health Data 1998. Paris: Organisation for Economic Co-operation and Development, 1998.